Clinical trials: Pulmonary Hypertension, Primary
Hypertension, Pulmonary
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life…
- Trial name
- CAPTURE (NCT02545465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension
The objective of the study is to monitor physical activity longitudinally with a wrist activity tracker specifically in PAH patients newly initiating ERA therapy and to assess the correlation with the 6MWD at different time…
- Trial name
- LONGACT (NCT02309463)
- Testing
- Endothelin receptor antagonist therapy
- Sponsor
- Actelion
Hypertension, Diabetes
Retrieval of Economic Incentives and Information on Quality-of-care Indicators in Primary Care
Background: Information provision and economic incentives for professionals are measures aimed at improving quality-of-care in primary care.
- Conditions
- Hypertension, Diabetes, Atrium; Fibrillation, Asthma
- Trial name
- NCT06829589
- Testing
- Removal of economic incentives linked to 7 quality-of-care indicators, Removal of information provision linked to 7 quality-of-care indicators
- Where
- 68 sites in Spain
- Volunteers
- 1,614 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Pulmonary Hypertension
Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients
This multicenter, open label, double-arm study aims at investigating the the continuous effect of long-Term rehabilitation training on clinical improvement(ITTCI) and cardiopulmonary function in pulmonary arterial hypertension…
- Trial name
- NCT07149935
- Testing
- Rehabilitation Training
- Where
- China
- Volunteers
- 104 people
- Sponsor
- RenJi Hospital
Pulmonary Arterial Hypertension
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation
- Trial name
- ADAPT (NCT03045029)
- Testing
- Oral treprostinil
- Where
- 41 sites in United States
- Volunteers
- 300 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension, Eisenmenger Syndrome
Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart Defects
The purpose of this study is to investigate the influence of physical training on exercise capacity, quality of life, functional class, oxygen consumption and right ventricular function in patients with severe associated…
- Trial name
- NCT01397110
- Testing
- respiratory and exercise therapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Eisenmenger Syndrome
Bosentan in Treatment of Pulmonary Arterial Hypertension
Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that constitutes a great burden at the individual as well as the familial and social level.
- Trial name
- NCT00266162
- Testing
- Bosentan administration
- Where
- 8 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Competence Network for Congenital Heart Defects
PAH
Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension
The objective of this research project is to evaluate the biological effects of long-chain omega-3 supplementation, administered in an optimized, high-purity formulation (EPA:DHA 6:1, >95% v/v), as an adjunct to standard-of-care…
- Trial name
- OMEGA-PAH (NCT07697235)
- Testing
- OMega 3
- Volunteers
- 22 people
- Sponsor
- University Hospital, Strasbourg, France
Aortic Valve Stenosis, Pulmonary Hypertension
Prognostic Impact of the Evolution of PAH 3 Months After TAVI (HTP-TAVI)
Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population.
- Trial name
- HTP-TAVI (NCT04008550)
- Testing
- Right Heart Catheterization
- Where
- France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Rouen
Pulmonary Arterial Hypertension, Exercise Training
Home-based Exercise Training in Patients With Pulmonary Arterial Hypertension: Effect on Skeletal Muscular Function and Metabolism
Pulmonary Arterial Hypertension has gone from a disease that causes rapid death to a more chronic condition. Yet, improved survival is associated with major challenges for clinicians as most patients remain with poor quality of…
- Conditions
- Pulmonary Arterial Hypertension, Exercise Training, Home-based Rehabilitation, Exercise Capacity
- Trial name
- NCT04241497
- Testing
- Home-based rehabilitation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Laval University
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Biomarkers in the Evaluation of Chronic Lung Disease
We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a…
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease
- Trial name
- NCT00926523
- Testing
- Blood Gas, Pulmonary Exercise Test, Spirometry
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Healthy, Healthy Adult
Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level and re-ascent from sea level to 2850m on heart rate variability and other hemodynamic parameters in healthy individuals, who live…
- Conditions
- Healthy, Healthy Adult, High Altitude Effects, High Altitude
- Trial name
- NCT07801846
- Testing
- Descent and re-ascent (2850m, sea level)
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension
Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease
The prevalence of PAH associated with congenital systemic-to-pulmonary shunts in Western countries has been estimated to range between 1.6 and 12.5 cases per million adults, with 25-50% of this population affected by…
- Trial name
- EIGER (NCT01383083)
- Volunteers
- 42 people
- Sponsor
- Maryknoll Medical Center
Pulmonary Arterial Hypertension (PAH)
TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends
TRESPECT is an international, multicenter, observational registry designed to describe the real-world use, effectiveness, and tolerability of parenteral treprostinil in adults with newly diagnosed pulmonary arterial hypertension…
- Trial name
- NCT07736846
- Testing
- treprostinil
- Volunteers
- 300 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Hypertension, Pulmonary
Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
The objective of this post-marketing surveillance study is to evaluate the incidence of adverse events in Japanese subjects with pulmonary arterial hypertension treated with ambrisentan basd on prescribing information under the…
- Trial name
- NCT01406327
- Testing
- Ambrisentan
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- NCT05462574
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial…
- Trial name
- FUTURE 2 (NCT00319020)
- Testing
- Bosentan
- Volunteers
- 33 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Healthy
Right Ventricular Metabolism in Pulmonary Arterial Hypertension
The purpose of this study is to use non-invasive imaging to determine the metabolic phenotype of the right ventricle in patients with pulmonary arterial hypertension across a spectrum of disease severity.
- Trial name
- NCT02763735
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Hypertension
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
This pilot, non-interventional, company-sponsored, multi-center study documents observational data on patients under routine treatment of Pulmonary Arterial Hypertension (PAH) with inhaled iloprost (using I-Neb device for the…
- Trial name
- COMPHI (NCT01894035)
- Testing
- Iloprost (Ventavis, BAYQ 6256)
- Where
- Portugal
- Volunteers
- 13 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
The purpose of this study is: To investigate CYP2C9 inhibition by BIA 5-1058 through the assessment of its effect on the Pharmacokinetic (PK) of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT04994119
- Testing
- BIA 5-1058, Warfarin
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.